Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenerimod in Systemic Lupus Erythematosus
NCT05672576Phase 3Active, not recruiting
- Sponsor
- Viatris
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of cenerimod in systemic lupus erythematosus (SLE), sponsored by Viatris. Started Jun 2023; status: active, not recruiting.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05672576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672576.